Last reviewed · How we verify
Plasma-Lyte A
Plasma-Lyte A is a balanced crystalloid electrolyte solution that replaces fluid and electrolytes lost through dehydration, hemorrhage, or other causes.
Plasma-Lyte A is a balanced crystalloid electrolyte solution that replaces fluid and electrolytes lost through dehydration, hemorrhage, or other causes. Used for Fluid and electrolyte replacement in dehydration, Perioperative fluid management, Hemorrhage and hypovolemia management.
At a glance
| Generic name | Plasma-Lyte A |
|---|---|
| Sponsor | Michael A. Matthay |
| Drug class | Crystalloid fluid replacement solution |
| Modality | Biologic |
| Therapeutic area | Critical Care / Fluid Management |
| Phase | FDA-approved |
Mechanism of action
Plasma-Lyte A contains a physiologically balanced mixture of sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate ions in concentrations approximating plasma. It is administered intravenously to restore intravascular volume and correct electrolyte imbalances, with a pH and osmolality designed to minimize metabolic disturbances compared to normal saline.
Approved indications
- Fluid and electrolyte replacement in dehydration
- Perioperative fluid management
- Hemorrhage and hypovolemia management
- Maintenance of electrolyte balance in hospitalized patients
Common side effects
- Hyperkalemia
- Hypokalemia
- Hyperchloremic acidosis (less common than with normal saline)
- Fluid overload / pulmonary edema
- Hyponatremia
Key clinical trials
- Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy (PHASE2)
- Precision Resuscitation With Crystalloids in Sepsis (NA)
- Descartes-08 in Autoantibody Myositis (PHASE2)
- Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge (PHASE1)
- Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis (PHASE3)
- Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML) (PHASE1, PHASE2)
- Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE) (PHASE2)
- CReep and Maintenance flUid Sodium Chloride ADministration rEduction in cRitically Ill adultS (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Plasma-Lyte A CI brief — competitive landscape report
- Plasma-Lyte A updates RSS · CI watch RSS
- Michael A. Matthay portfolio CI